February 7, 2014
Asahi Kasei Pharma Corp.
Asahi Kasei Pharma (headquarters: Tokyo, Japan; President: Toshio Asano) has completed the construction of the second manufacturing facility at its Nagoya Pharmaceuticals Plant (Miyoshi, Aichi, Japan), and today held its Grand Opening Ceremony.
The new facility will be used to manufacture Asahi Kasei Pharma’s flagship products Teribone™ osteoporosis drug and Recomodulin™ anticoagulant. As well as ensuring stable product supply and enhancing manufacturing technology, it will better facilitate compliance with increasingly stringent GMP (Good Manufacturing Practice) standards.
Asahi Kasei Pharma will continue to further enhance its manufacturing capabilities for the stable provision of high-quality products for patients.
Overview of the manufacturing facility
| Location: | Miyoshi, Aichi, Japan | |
|---|---|---|
| Structure: | Two stories above ground, with total floor area of 5,200 m2 | |
| Completion: | February 7, 2014 | |
| Start of utilization: | May 2014 | |
| Approximate investment: | ¥3.4 billion | |
| Products manufactured: | Teribone™ 56.5 µg subcutaneous injection formulation, Recomodulin™ anticoagulant intravenous infusion 12800 |
The second manufacturing facility at the Nagoya Pharmaceuticals Plant
Adobe Readeris required to view these PDF files.